Compare NWN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NWN | GENB |
|---|---|---|
| Founded | 1859 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2018 | 2026 |
| Metric | NWN | GENB |
|---|---|---|
| Price | $47.08 | $15.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $54.33 | $23.20 |
| AVG Volume (30 Days) | 193.2K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ 36.45 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,289,363,000.00 | N/A |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $4.46 | $16.58 |
| P/E Ratio | $20.16 | ★ N/A |
| Revenue Growth | ★ 11.83 | N/A |
| 52 Week Low | $43.64 | $11.00 |
| 52 Week High | $55.99 | $22.67 |
| Indicator | NWN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 44.03 |
| Support Level | $45.72 | $14.89 |
| Resistance Level | $47.51 | $16.75 |
| Average True Range (ATR) | 0.83 | 0.96 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 17.60 | 5.61 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.